By Bruce Levine, Ph.D., Barbara and Edward Netter professor in cancer gene therapy, University of Pennsylvania; president, International Society for Cell & Gene Therapy
The tragic combination of infectiousness and lethality of SARS-CoV-2 and COVID-19 has been the greatest public health emergency of the past 100 years. But there is a way forward through science, discovery, translation, and execution.
With the approvals of tisagenlecleucel (KYMRIAH) and axicabtagene ciloleucel (YESCARTA) last year, CAR T-cell therapies have changed the treatment paradigm for patients with certain hematologic malignancies. This blog breaks down the development of CAR T-cell therapy as well as its advantages and challenges.
By John Taylor, MilliporeSigma and Luan Truong, WuXi Advanced Therapies
One of the new technologies emerging in the biotech manufacturing market is the use of viral vectors for cell and gene therapy. One commonly used viral vector in this space is lentivirus, due to its robustness to package and deliver target DNA. This work explores a variety of lentivirus harvest clarification options and items for consideration during manufacturing platform development of viral therapy production using suspension cell lines.
Connect With Cell & Gene: